Investigational drug · Phase 3
ABP 234
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC), Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: May 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "ABP 234"
First trial start
2024
Sep 9, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABP 234", any sponsor or status.
Conditions studied
As listed on its trial records.
- Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
- Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "ABP 234" as an intervention, largest first.
- A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung CancerPivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06311721 · 315 participants · Start Sep 9, 2024 · Primary completion Jan 10, 2028
Drug: ABP 234; Pembrolizumab (US) and 1 more · For: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
Sites: Beverly Hills, California; Cerritos, California; Los Alamitos, California · 218 sites in all
- Pharmacokinetic Similarity Between ABP 234 and Keytruda® (Pembrolizumab)Pivotal-lookingActive, not recruiting
AmgenAmgen (AMGN)
NCT06430866 · 163 participants · Start Sep 12, 2024 · Primary completion Dec 14, 2026
Drug: ABP 234; Pembrolizumab · For: Early-stage Non-squamous Non-small Cell Lung Cancer (NSCLC)
Sites: San Salvador de Jujuy, Argentina; Rosario, Argentina; Córdoba, Argentina · 128 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Amgen.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.